BioSpecifics Technologies Stock Price, News & Analysis (NASDAQ:BSTC)

$43.20 0.06 (0.14 %)
(As of 12/13/2017 11:54 AM ET)
Previous Close$43.14
Today's Range$42.63 - $43.86
52-Week Range$41.95 - $58.79
Volume11,000 shs
Average Volume26,477 shs
Market Capitalization$310.14 million
P/E Ratio27.13
Dividend YieldN/A
Beta1.58

About BioSpecifics Technologies (NASDAQ:BSTC)

BioSpecifics Technologies logoBioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe). The two marketed indications involving its injectable collagenase are Dupuytren's contracture and Peyronie's disease. The other clinical indications for which its collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. The Company is evaluating its options for development of additional indications using collagenase.

Receive BSTC News and Ratings via Email

Sign-up to receive the latest news and ratings for BSTC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:BSTC
CUSIP09093110
Phone516-593-7000

Debt

Debt-to-Equity RatioN/A
Current Ratio30.93%
Quick Ratio30.93%

Price-To-Earnings

Trailing P/E Ratio27.13
Forward P/E Ratio27.52
P/E GrowthN/A

Sales & Book Value

Annual Sales$26.25 million
Price / Sales11.83
Cash Flow$1.83 per share
Price / Cash23.60
Book Value$7.87 per share
Price / Book5.49

Profitability

Trailing EPS$1.59
Net Income$11.37 million
Net Margins42.40%
Return on Equity19.11%
Return on Assets16.84%

Miscellaneous

Employees5
Outstanding Shares7,190,000

BioSpecifics Technologies (NASDAQ:BSTC) Frequently Asked Questions

What is BioSpecifics Technologies' stock symbol?

BioSpecifics Technologies trades on the NASDAQ under the ticker symbol "BSTC."

How were BioSpecifics Technologies' earnings last quarter?

BioSpecifics Technologies Corp (NASDAQ:BSTC) announced its earnings results on Friday, November, 10th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.36 by $0.01. The biopharmaceutical company had revenue of $6.52 million for the quarter, compared to analyst estimates of $6.59 million. BioSpecifics Technologies had a net margin of 42.40% and a return on equity of 19.11%. View BioSpecifics Technologies' Earnings History.

When will BioSpecifics Technologies make its next earnings announcement?

BioSpecifics Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, March, 21st 2018. View Earnings Estimates for BioSpecifics Technologies.

Where is BioSpecifics Technologies' stock going? Where will BioSpecifics Technologies' stock price be in 2017?

1 brokers have issued twelve-month price objectives for BioSpecifics Technologies' stock. Their predictions range from $65.00 to $65.00. On average, they anticipate BioSpecifics Technologies' share price to reach $65.00 in the next twelve months. View Analyst Ratings for BioSpecifics Technologies.

What are Wall Street analysts saying about BioSpecifics Technologies stock?

Here are some recent quotes from research analysts about BioSpecifics Technologies stock:

  • 1. According to Zacks Investment Research, "BIOSPECIFICS TECHNOLOGIES is engaged in the business of producing and licensing, for sale by other, a U.S. Food and Drug Administration (FDA) approved enzyme derived from collagenase, named Collagenase ABC, and researching, developing and clinically testing additional products derived therefrom for potential use as pharmaceuticals. " (10/10/2017)
  • 2. HC Wainwright analysts commented, "We have adjusted our revenue projection for BSTC accordingly, and our current 2017 revenue projection is $28.0M vs. the prior $29.6M, suggesting 7% YoY growth, while our 2018 revenue estimate is now $29.4M vs. the prior $32M." (8/10/2017)

Who are some of BioSpecifics Technologies' key competitors?

Who are BioSpecifics Technologies' key executives?

BioSpecifics Technologies' management team includes the folowing people:

  • Thomas L. Wegman, President, Principal Executive Officer, Principal Financial Officer, Director (Age 60)
  • Mark N. Wegman Ph.D., Director (Age 65)
  • Toby Wegman, Director (Age 80)
  • Jennifer M. Chao, Independent Director (Age 45)
  • Paul A. Gitman M.D., Independent Director (Age 74)
  • Jyrki Mattila M.D. Ph.D., Independent Director (Age 62)

Who owns BioSpecifics Technologies stock?

BioSpecifics Technologies' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (3.75%), Stonepine Capital Management LLC (2.94%), Eagle Asset Management Inc. (2.59%), Elk Creek Partners LLC (2.37%), Rice Hall James & Associates LLC (2.18%) and Northpointe Capital LLC (1.89%). Company insiders that own BioSpecifics Technologies stock include Thomas Wegman and Toby Wegman. View Institutional Ownership Trends for BioSpecifics Technologies.

Who sold BioSpecifics Technologies stock? Who is selling BioSpecifics Technologies stock?

BioSpecifics Technologies' stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., OxFORD Asset Management LLP, New York State Common Retirement Fund, Wells Fargo & Company MN, Rice Hall James & Associates LLC, American Century Companies Inc., GSA Capital Partners LLP and First Manhattan Co.. View Insider Buying and Selling for BioSpecifics Technologies.

Who bought BioSpecifics Technologies stock? Who is buying BioSpecifics Technologies stock?

BioSpecifics Technologies' stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Northpointe Capital LLC, Elk Creek Partners LLC, Los Angeles Capital Management & Equity Research Inc., Dimensional Fund Advisors LP, Schwab Charles Investment Management Inc., Eagle Asset Management Inc. and Cadence Capital Management LLC. View Insider Buying and Selling for BioSpecifics Technologies.

How do I buy BioSpecifics Technologies stock?

Shares of BioSpecifics Technologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioSpecifics Technologies' stock price today?

One share of BioSpecifics Technologies stock can currently be purchased for approximately $43.20.

How big of a company is BioSpecifics Technologies?

BioSpecifics Technologies has a market capitalization of $310.14 million and generates $26.25 million in revenue each year. The biopharmaceutical company earns $11.37 million in net income (profit) each year or $1.59 on an earnings per share basis. BioSpecifics Technologies employs 5 workers across the globe.

How can I contact BioSpecifics Technologies?

BioSpecifics Technologies' mailing address is 35 Wilbur Street, Lynbrook NY, 11563. The biopharmaceutical company can be reached via phone at 516-593-7000 or via email at [email protected]


MarketBeat Community Rating for BioSpecifics Technologies (BSTC)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  160
MarketBeat's community ratings are surveys of what our community members think about BioSpecifics Technologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioSpecifics Technologies (NASDAQ:BSTC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $62.50$62.50$66.00$60.00
Price Target Upside: 44.01% upside43.25% upside36.93% upside31.09% upside

BioSpecifics Technologies (NASDAQ:BSTC) Consensus Price Target History

Price Target History for BioSpecifics Technologies (NASDAQ:BSTC)

BioSpecifics Technologies (NASDAQ:BSTC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/11/2017HC WainwrightReiterated RatingBuyLowView Rating Details
8/10/2016Rodman & RenshawReiterated RatingBuy$60.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

BioSpecifics Technologies (NASDAQ:BSTC) Earnings History and Estimates Chart

Earnings by Quarter for BioSpecifics Technologies (NASDAQ:BSTC)

BioSpecifics Technologies (NASDAQ BSTC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2018        
11/10/2017Q3 2017$0.36$0.37$6.59 million$6.52 millionViewN/AView Earnings Details
3/15/2017Q4 2016$0.38$0.40$6.76 million$6.62 millionViewN/AView Earnings Details
11/9/2016Q3 2016$0.41$0.42$6.95 million$6.88 millionViewListenView Earnings Details
8/9/2016Q216$0.35$0.35$6.25 million$6.20 millionViewN/AView Earnings Details
5/10/2016Q116$0.37$0.39$6.25 million$6.60 millionViewListenView Earnings Details
3/14/2016Q416$0.33$0.36$4.60 million$6.10 millionViewListenView Earnings Details
11/9/2015Q315$0.39$7.51 million$6.30 millionViewN/AView Earnings Details
8/10/2015Q215$0.44$0.24$2.60 million$4.70 millionViewListenView Earnings Details
5/11/2015Q414$0.32$2.30 million$5.60 millionViewN/AView Earnings Details
11/10/2014Q314$0.19$0.20$4.00 million$4.00 millionViewN/AView Earnings Details
8/11/2014Q214$0.12$0.08$2.91 million$2.70 millionViewN/AView Earnings Details
5/8/2014Q114$0.07$0.11$2.46 million$2.80 millionViewN/AView Earnings Details
3/6/2014$0.17$0.25ViewN/AView Earnings Details
11/12/2013Q3$0.04$0.17ViewListenView Earnings Details
8/8/2013Q2 2013$0.02$0.15ViewN/AView Earnings Details
5/10/2013Q1 2013$0.18$0.19ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

BioSpecifics Technologies (NASDAQ:BSTC) Earnings Estimates

Current Year EPS Consensus Estimate: $1.57 EPS
Next Year EPS Consensus Estimate: $1.59 EPS

Dividends

Dividend History for BioSpecifics Technologies (NASDAQ:BSTC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

BioSpecifics Technologies (NASDAQ BSTC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.54%
Institutional Ownership Percentage: 56.12%
Insider Trades by Quarter for BioSpecifics Technologies (NASDAQ:BSTC)
Institutional Ownership by Quarter for BioSpecifics Technologies (NASDAQ:BSTC)

BioSpecifics Technologies (NASDAQ BSTC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/29/2016Thomas WegmanInsiderSell20,000$48.16$963,200.00View SEC Filing  
11/29/2016Toby WegmanDirectorSell10,000$48.08$480,800.00View SEC Filing  
9/15/2016Thomas WegmanInsiderSell3,100$41.21$127,751.00View SEC Filing  
9/13/2016Thomas WegmanInsiderSell3,605$37.55$135,367.75View SEC Filing  
9/2/2016Thomas WegmanInsiderSell9,201$37.53$345,313.53View SEC Filing  
8/30/2016Thomas WegmanInsiderSell4,299$37.54$161,384.46View SEC Filing  
8/24/2016Thomas WegmanPresidentSell4,173$38.08$158,907.84View SEC Filing  
8/23/2016Thomas WegmanPresidentSell4,100$38.60$158,260.00View SEC Filing  
5/18/2016Thomas WegmanMajor ShareholderSell50,000$33.01$1,650,500.00View SEC Filing  
5/18/2016Toby WegmanDirectorSell25,000$33.01$825,250.00View SEC Filing  
11/30/2015Thomas WegmanCEOSell2,000$50.00$100,000.00View SEC Filing  
11/23/2015Thomas WegmanCEOSell14,000$50.09$701,260.00View SEC Filing  
11/18/2015Thomas WegmanCEOSell10,849$50.08$543,317.92View SEC Filing  
11/16/2015Thomas WegmanCEOSell27,151$52.44$1,423,798.44View SEC Filing  
7/20/2015Paul GitmanDirectorSell8,692$53.00$460,676.00View SEC Filing  
6/23/2015Paul GitmanDirectorSell36,308$51.78$1,880,028.24View SEC Filing  
5/29/2015Paul GitmanDirectorSell15,000$46.76$701,400.00View SEC Filing  
5/27/2015Paul GitmanDirectorSell24,000$42.00$1,008,000.00View SEC Filing  
1/23/2015Paul GitmanDirectorSell5,887$41.00$241,367.00View SEC Filing  
1/16/2015Paul GitmanDirectorSell4,113$41.00$168,633.00View SEC Filing  
11/24/2014Toby WegmanDirectorSell12,050$39.07$470,793.50View SEC Filing  
11/14/2014Michael SchamrothDirectorSell5,200$39.20$203,840.00View SEC Filing  
11/14/2014Thomas WegmanMajor ShareholderSell40,000$38.96$1,558,400.00View SEC Filing  
6/20/2014Jeffrey Kenneth VogelInsiderSell88,329$27.43$2,422,864.47View SEC Filing  
6/12/2014Paul GitmanDirectorSell10,000$28.00$280,000.00View SEC Filing  
6/4/2014Henry MorganDirectorSell17,940$27.00$484,380.00View SEC Filing  
6/2/2014Henry MorganDirectorSell2,060$27.01$55,640.60View SEC Filing  
5/29/2014Henry MorganDirectorSell20,000$27.03$540,600.00View SEC Filing  
5/19/2014Henry MorganDirectorSell20,000$25.84$516,800.00View SEC Filing  
1/23/2014Paul GitmanDirectorSell10,000$25.00$250,000.00View SEC Filing  
12/9/2013Paul GitmanDirectorSell15,000$23.00$345,000.00View SEC Filing  
11/11/2013Paul GitmanDirectorSell5,000$20.00$100,000.00View SEC Filing  
9/5/2013Henry MorganDirectorSell17,850$18.48$329,868.00View SEC Filing  
9/3/2013Henry MorganDirectorSell2,150$18.35$39,452.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioSpecifics Technologies (NASDAQ BSTC) News Headlines

Source:
DateHeadline
Financial Survey: BioSpecifics Technologies (BSTC) versus Its RivalsFinancial Survey: BioSpecifics Technologies (BSTC) versus Its Rivals
www.americanbankingnews.com - December 13 at 3:28 AM
 BioSpecifics Technologies Corp (BSTC) Given $65.00 Average Target Price by Brokerages BioSpecifics Technologies Corp (BSTC) Given $65.00 Average Target Price by Brokerages
www.americanbankingnews.com - December 11 at 9:50 PM
BioSpecifics Technologies (BSTC) Buy Rating Reaffirmed at HC WainwrightBioSpecifics Technologies' (BSTC) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - December 11 at 9:00 AM
 BioSpecifics Technologies Corp (BSTC) Receives Average Recommendation of "Strong Buy" from Brokerages BioSpecifics Technologies Corp (BSTC) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - December 7 at 5:30 AM
Biospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : December 5, 2017Biospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : December 5, 2017
finance.yahoo.com - December 5 at 9:47 AM
Biospecifics Technologies Corp. :BSTC-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017Biospecifics Technologies Corp. :BSTC-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017
finance.yahoo.com - December 5 at 9:47 AM
Should You Be Tempted To Buy BioSpecifics Technologies Corp (BSTC) Because Of Its PE Ratio?Should You Be Tempted To Buy BioSpecifics Technologies Corp (BSTC) Because Of Its PE Ratio?
finance.yahoo.com - November 28 at 5:39 PM
Zacks: BioSpecifics Technologies Corp (BSTC) Receives Average Rating of "Strong Buy" from BrokeragesZacks: BioSpecifics Technologies Corp (BSTC) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - November 21 at 11:42 AM
BioSpecifics Technologies Corp (BSTC) PT Lowered to $65.00 at BioSpecifics Technologies Corp (BSTC) PT Lowered to $65.00 at
www.americanbankingnews.com - November 19 at 4:20 PM
BioSpecifics Technologies Corp (BSTC) Posts Quarterly  Earnings Results, Beats Expectations By $0.01 EPSBioSpecifics Technologies Corp (BSTC) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - November 11 at 10:38 AM
BioSpecifics Technologies Corp. Reports Third Quarter 2017 Financial ResultsBioSpecifics Technologies Corp. Reports Third Quarter 2017 Financial Results
www.bizjournals.com - November 10 at 12:34 PM
ETFs with exposure to Biospecifics Technologies Corp. : November 8, 2017ETFs with exposure to Biospecifics Technologies Corp. : November 8, 2017
finance.yahoo.com - November 8 at 7:35 PM
BioSpecifics Technologies Corp. to Present at the Stifel 2017 Healthcare ConferenceBioSpecifics Technologies Corp. to Present at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 7 at 7:41 PM
 BioSpecifics Technologies Corp (BSTC) Receives Consensus Rating of "Strong Buy" from Analysts BioSpecifics Technologies Corp (BSTC) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - November 6 at 3:36 PM
Biospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : October 18, 2017Biospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : October 18, 2017
finance.yahoo.com - October 18 at 6:05 PM
BioSpecifics Technologies Corp (BSTC) Raised to Hold at Zacks Investment ResearchBioSpecifics Technologies Corp (BSTC) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - October 10 at 8:24 PM
Biospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : October 3, 2017Biospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : October 3, 2017
finance.yahoo.com - October 3 at 8:35 AM
One Thing To Consider Before Buying BioSpecifics Technologies Corp (BSTC)One Thing To Consider Before Buying BioSpecifics Technologies Corp (BSTC)
finance.yahoo.com - October 2 at 7:29 PM
BioSpecifics Technologies Corp. to Present at the 2017 Cantor Fitzgerald Global Healthcare ConferenceBioSpecifics Technologies Corp. to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 5:34 PM
Biospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : September 18, 2017Biospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : September 18, 2017
finance.yahoo.com - September 18 at 5:07 PM
Should You Buy BioSpecifics Technologies Corp (BSTC) At This PE Ratio?Should You Buy BioSpecifics Technologies Corp (BSTC) At This PE Ratio?
finance.yahoo.com - September 15 at 10:11 PM
BioSpecifics Tech (BSTC) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowBioSpecifics Tech (BSTC) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 4:08 AM
Biospecifics Technologies Corp. :BSTC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017Biospecifics Technologies Corp. :BSTC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
finance.yahoo.com - September 13 at 5:58 PM
BioSpecifics Technologies Corp. Reports Second Quarter 2017 Financial ResultsBioSpecifics Technologies Corp. Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 4:56 PM
Biospecifics Technologies Corp. – Value Analysis (NASDAQ:BSTC) : August 4, 2017Biospecifics Technologies Corp. – Value Analysis (NASDAQ:BSTC) : August 4, 2017
finance.yahoo.com - August 3 at 11:19 PM
Biospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : July 21, 2017Biospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : July 21, 2017
finance.yahoo.com - July 21 at 6:21 PM
 BioSpecifics Technologies Corp (NASDAQ:BSTC) Given Average Recommendation of "Strong Buy" by Brokerages BioSpecifics Technologies Corp (NASDAQ:BSTC) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - July 21 at 11:18 AM
ETFs with exposure to Biospecifics Technologies Corp. : July 11, 2017ETFs with exposure to Biospecifics Technologies Corp. : July 11, 2017
finance.yahoo.com - July 11 at 5:47 PM
Biospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : July 10, 2017Biospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : July 10, 2017
finance.yahoo.com - July 10 at 3:15 PM
BioSpecifics Technologies (BSTC) Presents At Jefferies 2017 Global Healthcare ConferenceBioSpecifics Technologies (BSTC) Presents At Jefferies 2017 Global Healthcare Conference
seekingalpha.com - June 10 at 2:39 AM
BRIEF-Biospecifics Technologies reports Q1 earnings per share $0.46BRIEF-Biospecifics Technologies reports Q1 earnings per share $0.46
www.reuters.com - May 11 at 4:38 PM
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 10-K, Annual ReportBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 10-K, Annual Report
biz.yahoo.com - March 16 at 10:44 PM
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
biz.yahoo.com - March 15 at 9:25 PM
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Other EventsBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Other Events
biz.yahoo.com - February 16 at 8:54 AM
Biospecifics Technologies (BSTC) Reports Statistically Significant Results from Phase 2b Study of CCH in Patients with CelluliteBiospecifics Technologies (BSTC) Reports Statistically Significant Results from Phase 2b Study of CCH in Patients with Cellulite
www.streetinsider.com - November 19 at 12:23 PM
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - November 14 at 7:32 AM
BioSpecifics Technologies (BSTC) Management on Q3 2016 Results - Earnings Call TranscriptBioSpecifics Technologies' (BSTC) Management on Q3 2016 Results - Earnings Call Transcript
seekingalpha.com - November 10 at 3:21 PM
Q3 2016 Biospecifics Technologies Corp Earnings Release - Before Market OpenQ3 2016 Biospecifics Technologies Corp Earnings Release - Before Market Open
biz.yahoo.com - November 9 at 1:04 PM
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Entry into a Material Definitive AgreementBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - November 7 at 3:35 PM
Foamix Pharmaceuticals (FOMX) Jumps: Stock Rises 15.7%Foamix Pharmaceuticals (FOMX) Jumps: Stock Rises 15.7%
www.zacks.com - September 13 at 8:51 AM
New Strong Buy Stocks for September 7thNew Strong Buy Stocks for September 7th
www.zacks.com - September 7 at 10:32 AM
Dipexium Pharmaceuticals (DPRX) in Focus: Stock Gains 8.5%Dipexium Pharmaceuticals (DPRX) in Focus: Stock Gains 8.5%
www.zacks.com - September 1 at 12:28 PM
Weakness Seen in Jazz Pharmaceuticals (JAZZ) Estimates: Should You Stay Away?Weakness Seen in Jazz Pharmaceuticals (JAZZ) Estimates: Should You Stay Away?
www.zacks.com - August 29 at 3:20 PM
Q2 2016 Biospecifics Technologies Corp Earnings Release - Before Market OpenQ2 2016 Biospecifics Technologies Corp Earnings Release - Before Market Open
biz.yahoo.com - August 9 at 12:56 PM
BioSpecifics Technologies Corp. Has A 6-Year Expiration DateBioSpecifics Technologies Corp. Has A 6-Year Expiration Date
seekingalpha.com - August 3 at 12:41 PM
BioSpecifics Technologies Reveals Positive Top-Line Results From Stage 2 Study Of CCH For Treatment of Human LipomaBioSpecifics Technologies Reveals Positive Top-Line Results From Stage 2 Study Of CCH For Treatment of Human Lipoma
feeds.benzinga.com - June 13 at 10:19 AM
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - June 3 at 1:09 PM
Biospecifics Technologies (BSTC) Announces Publication of Data for Uterine Fibroid Treatment with CCHBiospecifics Technologies (BSTC) Announces Publication of Data for Uterine Fibroid Treatment with CCH
www.streetinsider.com - May 31 at 4:00 PM
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and ExhibitsBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - May 31 at 3:04 PM

SEC Filings

BioSpecifics Technologies (NASDAQ:BSTC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioSpecifics Technologies (NASDAQ:BSTC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioSpecifics Technologies (NASDAQ BSTC) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.